Copyright © 2012 Yasuko Kitagishi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. G. Thornicroft and M. Tansella, “The balanced care model for global mental health,” Psychological Medicine, pp. 1–15, 2012. View at Publisher · View at Google Scholar
2. S. E. Hammack, M. A. Cooper, and K. R. Lezak, “Overlapping neurobiology of learned helplessness and conditioned defeat: implications for PTSD and mood disorders,” Neuropharmacology, vol. 62, no. 2, pp. 565–575, 2012. View at Publisher · View at Google Scholar · View at Scopus
3. A.-M. Bao, H. G. Ruhé, S.-F. Gao, and D. F. Swaab, “Neurotransmitters and neuropeptides in depression,” Handbook of Clinical Neurology, vol. 106, pp. 107–136, 2012. View at Publisher · View at Google Scholar
4. M. Maes, M. Berk, L. Goehler et al., “Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways,” BMC Medicine, vol. 10, p. 66, 2012. View at Publisher · View at Google Scholar
5. A. R. Cole, “GSK3 as a sensor determining cell fate in the brain,” Frontiers in Molecular Neuroscience. In press. View at Publisher · View at Google Scholar
6. J.-M. Beaulieu, “A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health,” Journal of Psychiatry and Neuroscience, vol. 37, no. 1, pp. 7–16, 2012. View at Publisher · View at Google Scholar
7. L. Freland and J.-M. Beaulieu, “Inhibition of GSK3 by lithium, from single molecules to signaling networks,” Frontiers in Molecular Neuroscience, vol. 5, article 14, 2012. View at Publisher · View at Google Scholar
8. F. Benedetti, I. Bollettini, I. Barberi, et al., “Lithium and GSK3-β Promoter gene variants influence white matter microstructure in bipolar disorder,” Neuropsychopharmacology. In press. View at Publisher · View at Google Scholar
9. T. Del'guidice and J. M. Beaulieu, “Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo,” Molecular Pharmacology, vol. 73, no. 5, pp. 1339–1342, 2008. View at Publisher · View at Google Scholar · View at Scopus
10. R. L. Hauger, J. A. Olivares-Reyes, F. M. Dautzenberg, J. B. Lohr, S. Braun, and R. H. Oakley, “Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy,” Neuropharmacology, vol. 62, no. 2, pp. 705–714, 2012. View at Publisher · View at Google Scholar
11. R. K. Farooq, E. Isingrini, A. Tanti, et al., “Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation?” Behavioural Brain Research, vol. 231, no. 1, pp. 130–137, 2012.
12. T. Weichhart and M. D. Säemann, “The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications,” Annals of the Rheumatic Diseases, vol. 67, supplement 3, pp. iii70–iii74, 2008. View at Publisher · View at Google Scholar · View at Scopus
13. J. Y. Kim, X. Duan, C. Y. Liu et al., “DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212,” Neuron, vol. 63, no. 6, pp. 761–773, 2009. View at Publisher · View at Google Scholar · View at Scopus
14. J.-M. Beaulieu, R. R. Gainetdinov, and M. G. Caron, “Akt/GSK3 signaling in the action of psychotropic drugs,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 327–347, 2009. View at Publisher · View at Google Scholar
15. Z. You, C. Luo, W. Zhang et al., “Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement in depression,” Behavioural Brain Research, vol. 225, no. 1, pp. 135–141, 2011. View at Publisher · View at Google Scholar · View at Scopus
16. A. Spooren, K. Kolmus, G. Laureys et al., “Interleukin-6, a mental cytokine,” Brain Research Reviews, vol. 67, no. 1-2, pp. 157–183, 2011. View at Publisher · View at Google Scholar · View at Scopus
17. C. Song and H. Wang, “Cytokines mediated inflammation and decreased neurogenesis in animal models of depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 3, pp. 760–768, 2011. View at Publisher · View at Google Scholar
18. S. Moylan, M. Maes, N. R. Wray, and M. Berk, “The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications,” Molecular Psychiatry. In Press. View at Publisher · View at Google Scholar
19. L. Die, P. Yan, Z. J. Jiang, T. Min Hua, W. Cai, and L. Xing, “Glycogen synthase kinase-3 beta inhibitor suppresses Porphyromonas gingivalis lipopolysaccharide-induced CD40 expression by inhibiting nuclear factor-kappa B activation in mouse osteoblasts,” Molecular Immunology, vol. 52, no. 1, pp. 38–49, 2012. View at Publisher · View at Google Scholar
20. M. Haidinger, M. Poglitsch, R. Geyeregger et al., “A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation,” Journal of Immunology, vol. 185, no. 7, pp. 3919–3931, 2010. View at Publisher · View at Google Scholar · View at Scopus
21. B. Leonard and M. Maes, “Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression,” Neuroscience and Biobehavioral Reviews, vol. 36, no. 2, pp. 764–785, 2012. View at Publisher · View at Google Scholar
22. L. Sghendo and J. Mifsud, “Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model,” Journal of Pharmacy and Pharmacology, vol. 64, no. 3, pp. 317–325, 2012. View at Publisher · View at Google Scholar
23. D. J. David, J. Wang, B. A. Samuels et al., “Implications of the functional integration of adult-born hippocampal neurons in anxiety-depression disorders,” Neuroscientist, vol. 16, no. 5, pp. 578–591, 2010. View at Publisher · View at Google Scholar · View at Scopus
24. W. Young, “Review of lithium effects on brain and blood,” Cell Transplantation, vol. 18, no. 9, pp. 951–975, 2009. View at Publisher · View at Google Scholar · View at Scopus
25. D. Muyllaert, A. Kremer, T. Jaworski et al., “Glycogen synthase kinase-3β, or a link between amyloid and tau pathology?” Genes, Brain and Behavior, vol. 7, supplement 1, pp. 57–66, 2008. View at Publisher · View at Google Scholar · View at Scopus
26. A. Jazwa and A. Cuadrado, “Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases,” Current drug targets, vol. 11, no. 12, pp. 1517–1531, 2010. View at Scopus
27. N. K. Idriss, A. D. Blann, and G. Y. H. Lip, “Hemoxygenase-1 in cardiovascular disease,” Journal of the American College of Cardiology, vol. 52, no. 12, pp. 971–978, 2008. View at Publisher · View at Google Scholar
28. J. Hammond and J.-L. Balligand, “Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 2, pp. 330–340, 2012. View at Publisher · View at Google Scholar
29. A. E. Courtney and A. P. Maxwell, “Heme Oxygenase 1: does It have a role in renal cytoprotection?” The American Journal of Kidney Diseases, vol. 51, no. 4, pp. 678–690, 2008. View at Publisher · View at Google Scholar · View at Scopus
30. R. Hardeland, “Melatonin: signaling mechanisms of a pleiotropic agent,” BioFactors, vol. 35, no. 2, pp. 183–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
31. K. Sheppard, K. M. Kinross, B. Solomon, R. B. Pearson, and W. A. Phillips, “Targeting PI3 kinase/AKT/mTOR signaling in cancer,” Critical Reviews in Oncogenesis, vol. 17, no. 1, pp. 69–95, 2012.
32. E. Aksamitiene, A. Kiyatkin, and B. N. Kholodenko, “Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance,” Biochemical Society Transactions, vol. 40, no. 1, pp. 139–146, 2012. View at Publisher · View at Google Scholar
33. N. Okumura, H. Yoshida, Y. Kitagishi, and S. Matsuda, “PI3K/AKT/PTEN signaling as a molecular target in leukemia angiogenesis,” Advances in Hematology, vol. 2012, Article ID 843085, 6 pages, 2012. View at Publisher · View at Google Scholar
34. C. Gao, C. Hlscher, Y. Liu, and L. Li, “GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease,” Reviews in the Neurosciences, vol. 23, no. 1, pp. 1–11, 2012. View at Publisher · View at Google Scholar
35. M. S. Song, L. Salmena, and P. P. Pandolfi, “The functions and regulation of the PTEN tumour suppressor,” Nature Reviews Molecular Cell Biology, vol. 13, no. 5, pp. 283–296, 2012. View at Publisher · View at Google Scholar
36. R. A. Nemenoff, P. A. Simpson, S. B. Furgeson et al., “Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1α,” Circulation Research, vol. 102, no. 9, pp. 1036–1045, 2008. View at Publisher · View at Google Scholar · View at Scopus
37. N. Okumura, H. Yoshida, Y. Nishimura, Y. Kitagishi, and S. Matsuda, “Terpinolene, a component of herbal sage, downregulates AKT1 expression in K562 cells,” Oncology Letters, vol. 3, no. 2, pp. 321–324, 2012. View at Publisher · View at Google Scholar
38. M. G. Pezzolesi, P. Platzer, K. A. Waite, and C. Eng, “Differential expression of PTEN-Targeting microRNAs miR-19a and miR-21 in cowden syndrome,” The American Journal of Human Genetics, vol. 82, no. 5, pp. 1141–1149, 2008. View at Publisher · View at Google Scholar · View at Scopus
39. A. Zamani and Z. Qu, “Serotonin activates angiogenic phosphorylation signaling in human endothelial cells,” FEBS Letters, vol. 586, no. 16, pp. 2360–2365, 2012. View at Publisher · View at Google Scholar
40. M. Iwabayashi, Y. Taniyama, F. Sanada et al., “Role of serotonin in angiogenesis: induction of angiogenesis by sarpogrelate via endothelial 5-HT1B/Akt/eNOS pathway in diabetic mice,” Atherosclerosis, vol. 220, no. 2, pp. 337–342, 2012. View at Publisher · View at Google Scholar
41. A. Ahluwalia and A. S. Tarnawski, “Critical role of hypoxia sensor- HIF-1α in VEGF gene activation: implications for angiogenesis and tissue injury healing,” Current Medicinal Chemistry, vol. 19, no. 1, pp. 90–97, 2012.
42. J. Chen, P. R. Somanath, O. Razorenova et al., “Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo,” Nature Medicine, vol. 11, no. 11, pp. 1188–1196, 2005. View at Publisher · View at Google Scholar · View at Scopus
43. F. Shi, T.-Z. Zhao, S. Zhang et al., “Effects of simulated microgravity on human umbilical vein endothelial cell angiogenesis and role of the PI3K-Akt-eNOS signal pathway,” PLoS ONE, vol. 7, no. 7, Article ID 40365, 2012. View at Publisher · View at Google Scholar
44. C. K. Kim, S. B. Lee, T. L. X. Nguyen et al., “Long isoform of ErbB3 binding protein, p48, mediates protein kinase B/Akt-dependent HDM2 stabilization and nuclear localization,” Experimental Cell Research, vol. 318, no. 2, pp. 136–143, 2012. View at Publisher · View at Google Scholar
45. Q. Xu, L.-Z. Liu, X. Qian et al., “MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis,” Nucleic Acids Research, vol. 40, no. 2, pp. 761–774, 2012. View at Publisher · View at Google Scholar
46. J. E. Lee, J. S. Kang, Y.-W. Ki, S.-H. Lee, S.-J. Lee, and H. C. Koh, “Akt/GSK3β signaling is involved in fipronil-induced apoptotic cell death of human neuroblastoma SH-SY5Y cells,” Toxicology Letters, vol. 202, no. 2, pp. 133–141, 2011. View at Publisher · View at Google Scholar
47. E. S. Emamian, “AKT/GSK3 signaling pathway and schizophrenia,” Frontiers in Molecular Neuroscience, vol. 5, article 33, pp. 1–12, 2012. View at Publisher · View at Google Scholar
48. S. I. Yun, H. Y. Yoon, and Y. S. Chung, “Glycogen synthase kinase-3β regulates etoposide-induced apoptosis via Bcl-2 mediated caspase-3 activation in C3H10T1/2 cells,” Apoptosis, vol. 14, no. 6, pp. 771–777, 2009. View at Publisher · View at Google Scholar · View at Scopus
49. N. M. Enman and E. M. Unterwald, “Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse,” Behavioural Brain Research, vol. 231, no. 1, pp. 217–225, 2012. View at Publisher · View at Google Scholar
50. W. T. O'Brien and P. S. Klein, “Validating GSK3 as an in vivo target of lithium action,” Biochemical Society Transactions, vol. 37, no. 5, pp. 1133–1138, 2009. View at Publisher · View at Google Scholar · View at Scopus
51. T. Dal-Cim, S. Molz, J. Egea et al., “Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxigenase-1 via PI3K/Akt/GSK-3β pathway,” Neurochemistry International, vol. 61, no. 3, pp. 397–404, 2012. View at Publisher · View at Google Scholar
52. L. Mo, C. Yang, M. Gu et al., “PI3K/Akt signaling pathway-induced heme oxygenase-1 upregulation mediates the adaptive cytoprotection of hydrogen peroxide preconditioning against oxidative injury in PC12 cells,” International Journal of Molecular Medicine, vol. 30, no. 2, pp. 314–320, 2012. View at Publisher · View at Google Scholar
53. N. L. Neubauer, E. C. Ward, P. Patel et al., “Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis,” Hormones and Cancer, vol. 2, no. 3, pp. 170–181, 2011. View at Publisher · View at Google Scholar · View at Scopus
54. H. Zhou, Y. Luo, and S. Huang, “Updates of mTOR inhibitors,” Anti-Cancer Agents in Medicinal Chemistry, vol. 10, no. 7, pp. 571–581, 2010. View at Scopus
55. J. J. Gibbons, R. T. Abraham, and K. Yu, “Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth,” Seminars in Oncology, vol. 36, supplement 3, pp. S3–S17, 2009. View at Publisher · View at Google Scholar · View at Scopus
56. E. B. Larson and F. S. Zollman, “The effect of sleep medications on cognitive recovery from traumatic brain injury,” Journal of Head Trauma Rehabilitation, vol. 25, no. 1, pp. 61–67, 2010. View at Publisher · View at Google Scholar · View at Scopus
57. O. V. Forlenza, V. J. de Paula, R. MacHado-Vieira, B. S. Diniz, and W. F. Gattaz, “Does lithium prevent Alzheimers disease?” Drugs and Aging, vol. 29, no. 5, pp. 335–342, 2012. View at Publisher · View at Google Scholar
58. G. Chen, L. D. Huang, W. Z. Zeng, and H. K. Manji, “Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability,” International Journal of Neuropsychopharmacology, vol. 4, no. 1, pp. 47–64, 2001. View at Publisher · View at Google Scholar · View at Scopus
59. M. Maes, B. E. Leonard, A. M. Myint, M. Kubera, and R. Verkerk, “The new “5-HT” hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 3, pp. 702–721, 2011. View at Publisher · View at Google Scholar · View at Scopus